vatalanib has been researched along with Cancer of Liver in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (61.54) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Akita, H; Doki, Y; Eguchi, H; Hama, N; Katsura, Y; Kawamoto, K; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Tanemura, M; Umeshita, K; Wada, H | 1 |
| Chan, P; Fan, ST; Ng, K; Pang, R; Poon, RT; Yau, T | 1 |
| Doki, Y; Eguchi, H; Kobayashi, S; Marubashi, S; Mori, M; Murakami, M; Nagano, H; Noda, T; Takeda, Y; Tanemura, M; Tomimaru, Y; Umeshita, K; Wada, H | 1 |
| Ganslmayer, M; Herold, C; Zimmermann, A; Zopf, S | 1 |
| Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S | 1 |
| Drevs, J; Dugan, M; Laurent, D; Morgan, B; Steward, WP; Thomas, AL; Unger, C; Vanhoefer, U; Wiedenmann, B | 1 |
| Ellis, LM | 1 |
| Ball, HA; Buchert, M; Cherryman, GR; Drevs, J; Dugan, M; Fuxuis, S; Hennig, J; Henry, A; Horsfield, MA; Jivan, A; Laurent, D; Lee, L; Marmé, D; Mietlowski, W; Morgan, B; Mross, K; O'Byrne, K; Steward, WP; Thomas, AL; Unger, C | 1 |
| Alsop, DC; De Bazelaire, C; Duhamel, G; George, D; Michaelson, MD; Rofsky, NM | 1 |
| Fan, ST; Kok, TW; Lau, C; Li, Q; Liu, Y; Poon, RT | 1 |
| Drevs, J; Günther, C; Hennig, J; Ho, YY; Laurent, D; Lebwohl, D; Marmé, D; Masson, E; Medinger, M; Morgan, B; Mross, K; Müller, M; Unger, C | 1 |
| Allegrini, P; Brueggen, J; Cozens, R; Drevs, J; Guenther, C; Horsfield, M; Lebwohl, D; Lee, L; McSheehy, PM; Morgan, B; Schnell, C; Sharma, S; Steward, WP; Wood, J | 1 |
| Higginson, A; Horsfield, MA; Morgan, B; Steward, WP; Thomas, AL; Utting, JF | 1 |
2 review(s) available for vatalanib and Cancer of Liver
| Article | Year |
|---|---|
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays | 2012 |
Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Clinical Trials as Topic; Colorectal Neoplasms; Contrast Media; Drug Screening Assays, Antitumor; Gadolinium; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-1; Vascular Endothelial Growth Factor Receptor-2 | 2003 |
6 trial(s) available for vatalanib and Cancer of Liver
| Article | Year |
|---|---|
Phase 1-2 trial of PTK787/ZK222584 combined with intravenous doxorubicin for treatment of patients with advanced hepatocellular carcinoma: implication for antiangiogenic approach to hepatocellular carcinoma.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Hepatocellular; Doxorubicin; Drug Administration Schedule; Female; Humans; Infusions, Intravenous; Liver Neoplasms; Male; Middle Aged; Phthalazines; Pyridines | 2010 |
Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liv
Topics: Administration, Oral; Adult; Aged; Angiogenesis Inhibitors; Area Under Curve; Biomarkers; Colorectal Neoplasms; Contrast Media; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Phthalazines; Predictive Value of Tests; Pyridines; Treatment Outcome | 2003 |
Arterial spin labeling blood flow magnetic resonance imaging for the characterization of metastatic renal cell carcinoma(1).
Topics: Antineoplastic Agents; Bone Neoplasms; Carcinoma, Renal Cell; Cohort Studies; Contrast Media; Feasibility Studies; Female; Follow-Up Studies; Humans; Image Processing, Computer-Assisted; Kidney Neoplasms; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Magnetic Resonance Imaging; Male; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Regional Blood Flow; Spin Labels | 2005 |
Phase I clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours.
Topics: Administration, Oral; Adult; Aged; Analysis of Variance; Area Under Curve; Biomarkers, Tumor; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Male; Maximum Tolerated Dose; Middle Aged; Neovascularization, Pathologic; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Treatment Outcome; Ultrasonography, Doppler, Color | 2005 |
Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with
Topics: Angiogenesis Inhibitors; Animals; Biomarkers; Colorectal Neoplasms; Dogs; Drug Evaluation, Preclinical; Female; Humans; Liver Neoplasms; Magnetic Resonance Imaging; Melanoma, Experimental; Mice; Mice, Inbred C57BL; Phthalazines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor | 2006 |
A simple, reproducible method for monitoring the treatment of tumours using dynamic contrast-enhanced MR imaging.
Topics: Angiogenesis Inhibitors; Area Under Curve; Colorectal Neoplasms; Contrast Media; Drug Monitoring; Humans; Image Processing, Computer-Assisted; Liver Neoplasms; Lung Neoplasms; Magnetic Resonance Imaging; Phantoms, Imaging; Phthalazines; Pyridines; Receptors, Vascular Endothelial Growth Factor; Reproducibility of Results | 2006 |
5 other study(ies) available for vatalanib and Cancer of Liver
| Article | Year |
|---|---|
PTK787/ZK222584 combined with interferon alpha and 5-fluorouracil synergistically inhibits VEGF signaling pathway in hepatocellular carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Proliferation; Drug Synergism; Fluorouracil; Humans; Immunoenzyme Techniques; Interferon-alpha; Liver Neoplasms; Mice; Phthalazines; Protein Kinase Inhibitors; Pyridines; Signal Transduction; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A | 2013 |
Tyrosine kinase inhibitor PTK/ZK enhances the antitumor effects of interferon-α/5-fluorouracil therapy for hepatocellular carcinoma cells.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosis; Blotting, Western; Carcinoma, Hepatocellular; Cell Cycle; Cell Proliferation; Female; Flow Cytometry; Fluorouracil; Humans; Interferon-alpha; Liver Neoplasms; Mice; Mice, Inbred BALB C; Mice, Nude; Phthalazines; Protein Kinase Inhibitors; Pyridines; Receptors, Vascular Endothelial Growth Factor; Tumor Cells, Cultured | 2011 |
Combined inhibitors of angiogenesis and histone deacetylase: efficacy in rat hepatoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Benzamides; Drug Therapy, Combination; Histone Deacetylase Inhibitors; Liver Neoplasms; Liver Neoplasms, Experimental; Male; Phthalazines; Protein Kinase Inhibitors; Pyridines; Rats; Receptors, Vascular Endothelial Growth Factor; Tamoxifen; Tretinoin | 2011 |
Antiangiogenic therapy: more promise and, yet again, more questions.
Topics: Angiogenesis Inhibitors; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Colorectal Neoplasms; Humans; Liver Neoplasms; Neoplasm Metastasis; Phthalazines; Pyridines | 2003 |
Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584.
Topics: Angiogenesis Inhibitors; Animals; Apoptosis; bcl-X Protein; Carcinoma, Hepatocellular; Carrier Proteins; Caspase 3; Caspases; Cell Cycle Proteins; Cell Growth Processes; Cell Line, Tumor; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Extracellular Matrix Proteins; Humans; Intracellular Signaling Peptides and Proteins; Liver Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Myosin Heavy Chains; Neovascularization, Pathologic; Nonmuscle Myosin Type IIB; Phthalazines; Protein Kinase Inhibitors; Proteins; Proto-Oncogene Proteins c-bcl-2; Pyridines; Receptors, Vascular Endothelial Growth Factor; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2005 |